OTCMKTS:NVZMY - NOVOZYMES A/S/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NOVOZYMES A/S/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $48.50 -0.09 (-0.19 %) (As of 12/13/2019 04:00 PM ET) Add Compare Today's Range$48.37Now: $48.50▼$48.7550-Day Range$45.29MA: $47.38▼$49.2752-Week Range$39.96Now: $48.50▼$49.60Volume11,915 shsAverage Volume23,590 shsMarket Capitalization$14.40 billionP/E Ratio27.71Dividend Yield1.03%Beta0.77 ProfileAnalyst RatingsAdvanced ChartDividendEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. Read More… Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorBasic Materials Current SymbolOTCMKTS:NVZMY Previous Symbol CUSIPN/A CIKN/A Webhttp://www.novozymes.com/ Phone45-4446-0000Debt Debt-to-Equity Ratio0.23 Current Ratio1.29 Quick Ratio0.76Price-To-Earnings Trailing P/E Ratio27.71 Forward P/E Ratio30.89 P/E Growth2.45 Sales & Book Value Annual Sales$2.28 billion Price / Sales6.32 Cash Flow$1.73 per share Price / Cash Flow28.01 Book Value$6.10 per share Price / Book7.95Profitability EPS (Most Recent Fiscal Year)$1.75 Net Income$511 million Net Margins21.08% Return on Equity26.90% Return on Assets14.94%Miscellaneous Employees6,427 Outstanding Shares297,000,000Market Cap$14.40 billion Next Earnings Date1/23/2020 (Estimated) OptionableNot Optionable Receive NVZMY News and Ratings via Email Sign-up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter. OTC:NVZMY Rates by TradingView NOVOZYMES A/S/S (OTCMKTS:NVZMY) Frequently Asked Questions What is NOVOZYMES A/S/S's stock symbol? NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY." How often does NOVOZYMES A/S/S pay dividends? What is the dividend yield for NOVOZYMES A/S/S? NOVOZYMES A/S/S announced an annual dividend on Thursday, February 7th. Stockholders of record on Friday, March 1st will be paid a dividend of $0.504 per share on Tuesday, March 19th. This represents a dividend yield of 1.16%. The ex-dividend date of this dividend is Thursday, February 28th. View NOVOZYMES A/S/S's Dividend History. How were NOVOZYMES A/S/S's earnings last quarter? NOVOZYMES A/S/S (OTCMKTS:NVZMY) released its quarterly earnings data on Wednesday, October, 23rd. The biotechnology company reported $0.33 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by $0.10. The biotechnology company earned $551.80 million during the quarter, compared to analysts' expectations of $565.21 million. NOVOZYMES A/S/S had a net margin of 21.08% and a return on equity of 26.90%. View NOVOZYMES A/S/S's Earnings History. When is NOVOZYMES A/S/S's next earnings date? NOVOZYMES A/S/S is scheduled to release their next quarterly earnings announcement on Thursday, January 23rd 2020. View Earnings Estimates for NOVOZYMES A/S/S. What is the consensus analysts' recommendation for NOVOZYMES A/S/S? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NOVOZYMES A/S/S. Has NOVOZYMES A/S/S been receiving favorable news coverage? Headlines about NVZMY stock have trended positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NOVOZYMES A/S/S earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for NOVOZYMES A/S/S. Who are some of NOVOZYMES A/S/S's key competitors? Some companies that are related to NOVOZYMES A/S/S include Biogen (BIIB), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT) and Crispr Therapeutics (CRSP). What other stocks do shareholders of NOVOZYMES A/S/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other NOVOZYMES A/S/S investors own include ManpowerGroup (MAN), TeamHealth (TMH), Novo Nordisk A/S (NVO), DANSKE BK A/S/S (DNKEY), FOX (FOXA), Level One Bancorp (LEVL), Anadarko Petroleum (APC), Duke Energy (DUK), Emerson Electric (EMR) and Zayo Group (ZAYO). Who are NOVOZYMES A/S/S's key executives? NOVOZYMES A/S/S's management team includes the folowing people: Mr. Peder Holk Nielsen, Pres & CEO (Age 63)Dr. Prisca Havranek-Kosicek, CFO & Exec. VP of Corp. Functions (Age 44)Mr. Thomas Videbaek, Exectuive VP & COO of Research, Innovation & Supply (Age 59)Mr. Andrew Fordyce, Exec. VP of Food & Beverages (Age 56)Mr. Anders Lund, Exec. VP of Household Care & Technical Industries (Age 46) How do I buy shares of NOVOZYMES A/S/S? Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is NOVOZYMES A/S/S's stock price today? One share of NVZMY stock can currently be purchased for approximately $48.50. How big of a company is NOVOZYMES A/S/S? NOVOZYMES A/S/S has a market capitalization of $14.40 billion and generates $2.28 billion in revenue each year. The biotechnology company earns $511 million in net income (profit) each year or $1.75 on an earnings per share basis. NOVOZYMES A/S/S employs 6,427 workers across the globe.View Additional Information About NOVOZYMES A/S/S. What is NOVOZYMES A/S/S's official website? The official website for NOVOZYMES A/S/S is http://www.novozymes.com/. How can I contact NOVOZYMES A/S/S? NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected] MarketBeat Community Rating for NOVOZYMES A/S/S (OTCMKTS NVZMY)Community Ranking: 1.8 out of 5 ()Outperform Votes: 116 (Vote Outperform)Underperform Votes: 210 (Vote Underperform)Total Votes: 326MarketBeat's community ratings are surveys of what our community members think about NOVOZYMES A/S/S and other stocks. Vote "Outperform" if you believe NVZMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVZMY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2019 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?
